Full-Time

Executive Director

Hospital Marketing

Posted on 10/3/2025

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

King of Prussia, PA, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Product Management
Marketing
Requirements
  • BS/BA, MBA preferred
  • At least 15 years relevant health care (can include biologics, medical device or pharmaceuticals) sales/marketing or related experience including at least 8 years of US focused product management experience with launch of product or line extension and 7 or more years people management experience.
  • Must have demonstrated experience in contributing business input to early stage development projects.
  • Experience with buy & bill and in-patient hospital reimbursement and marketing / selling along with account management experience.
  • Experience in multiple therapeutic marketing and / or commercialization preferred
  • Understanding and prior experience of high cost biologic commercialization and reimbursement.
Responsibilities
  • Establishes and gains approval for strategic direction and marketing activities associated with multiple product portfolios, including product and LCM launches, that span numerous hospital based therapeutic areas and ensures active inputs from key stakeholders in medical affairs, sales, commercial development, clinical research and development, regulatory affairs, etc. Applies innovative and competitive strategies to the development of business plans for in-line and launch brands. Accountable for proactive management of marketing activities to assure compliance with internal Company and external requirements.
  • Leads the development and execution of the franchise and brand position, growth strategies and tactics for all products in franchise / therapeutic area. Gain management approval and organizational alignment by guiding development and presentation of one year annual planning and multi-year strategic planning.
  • Effectively engages and leads the franchise / brand decisions in partnership with Healthcare System teams (HCS) to ensure channel strategies, pricing and overall access strategy is aligned to brand objectives and financial goals.
  • Supports & engages all strategic and tactical management of the therapeutic area portfolio. Ensures the development of the annual business plan based on effective market definition, segmentation, clear definition of business opportunities and identification of appropriate business levers. Accountable for the successful implementation and measurement of commercial plans across multiple products in the hospital setting to maximize patient reach, revenue and market share. Ensures effective marketing representation on therapeutic area business (medical affairs, sales, commercial operations and marketing) teams.
  • Leads with a strong orientation on budgeting, forecasting and new capability building for the hospital franchise. Accountable for strategic plan and manufacturing plan forecasting in partnership with HCS and finance, including gaining stakeholder input on projections. Ensures proper inventory management for each product.
  • Develops and sustains an innovative, collaborative high performance culture for the business team. Leads an inclusive and growth based culture for performance with a focus on recruiting, developing and advance key talent within marketing.
  • Accountable for recommendations on brand and portfolio life-cycle management and gaining alignment on these from multiple stakeholder groups, including senior leadership. Is a member of the Global Therapeutic Area Leadership Team working closely with global partners to identify new product opportunities, accelerate the process of bringing packaging, administration, new products and line extension concepts to the U.S. market. Inputs into early stage product development to define Target Product Profile and Target Labeling.
  • Ensures US Commercial Operations input is provided in the development of Target Product Profiles, clinical research protocols and Target Labeling copy through appropriate channels – Therapeutic Area Leadership Teams, Global Project Review Committees, Global Launch Teams, etc. Represents regional priorities with therapeutic / franchise areas on Therapeutic Area Leadership Teams and ensures that the North American Commercial Operations position is reflected in all key projects.
  • Builds effective working relationships with key external customers, including thought leaders and patient advocacy groups across the entire range of therapeutic areas assigned. Ensures effective agency relationships are managed and developed in support of key initiatives. Selects and refines groups of vendors used for therapeutic area programs and projects and ensures alignment with therapeutic area marketing teams.
  • Has responsibility for oversight and effective management of all team members (i.e. direct and indirect reports) to include but not limited to the following:
  • Liaises with Government Reporting, Legal and Compliance to ensure compliance of all marketing programs.
  • Assures proper staff assignment and timely completion of appropriate training.
Desired Qualifications
  • Experience in multiple therapeutic marketing and / or commercialization preferred

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • HEMGENIX gene therapy sustains 37% factor IX levels through four years post-2025 data.
  • KOSTAIVE self-amplifying mRNA COVID vaccine approved by EC February 2025.
  • VarmX $2.2B acquisition option expands bleeding disorder pipeline in 2026.

What critics are saying

  • Seqirus separation triggers $500M charges and 14% revenue loss from Pentagon mandate scrap.
  • Grifols opens 20 plasma centers by 2027, eroding CSL Behring's immunoglobulin share.
  • Novartis Fabhalta displaces CSL Vifor's $1.5B nephrology revenues within 12 months.

What makes CSL unique

  • CSL Behring leads plasma-derived therapies for haemophilia and immunodeficiencies.
  • CSL Seqirus dominates influenza vaccines with global production scale.
  • CSL Vifor specializes in iron deficiency and nephrology treatments post-2022 acquisition.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Stock Titan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.

PharmiWeb.com
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb.com
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients

INACTIVE